No 8 (2017)

The inclusion of taurine in a daily dose of 750 mg in standard therapy of patients with coronary artery disease with chronic heart failure improves the functional class of heart failure, reduces the number of repeated hospitalizations due to decompensation of circulatory failure, but does not influence the overall mortality within 1 year. Against the background of taking the drug, the diastolic function of the left ventricle improves without significant dynamics in the size of the left chambers of the heart and the ejection fraction. The effectiveness of taurine in the treatment of patients is confirmed by a significant decrease in blood NT-proBNP and galectin-3 levels.

Peculiarities of anxiety disorders (AD), taking a leading place among illnesses, accompanying by vegetative nervous system disfunction, are considered. AD include generalized anxiety, panic, obscessive-compulsive and phobic disorders, and also posttraumatic stress disorder. Taking into account obligate coexistence of psychic symtomes of anxiety and its somatoneurological manifestations the term «psychovegetative disturbances» describing abovementioned symptom complex was adopted. Drugs of choice for AD treatment are selective serotonin reuptake inhibitors. Nevertheless, they have some disadvantages (slow getting the effect, side effects including sexual dysfunction). Benzodiazepines give fast antianxiety effect, but risk-benefit profile of these meducaments does not let to prescribe them for a long time. The question of possibilities of use of nonbenzodiazepine antianxiety remedies which are exeeding benzodiazepines for their safety for AD therapy is under detailed discussion.

Lumbar pain (LP) is one of the main causes of temporary disability and a decline in the quality of life. Modern approaches to the management of patients with LP, including pharmacotherapy and nondrug therapies, are considered. The advantages and disadvantages of the main groups of drugs used to treat such patients are discussed. From the standpoint of evidence-based medicine, the question of choosing the optimal therapeutic tactics is analyzed, which makes it possible to reduce the likelihood of unwanted side effects.

Acute respiratory viral infections (ARVI) along with influenza are the most common diseases both in adult and pediatric practices. Nowadays there are a lot of different medications to cure this condition, but it's still urgent to find some new drugs, which have a universal antiviral activity and also have proved effectiveness and safety, especially in case of treating patients with different allergic pathologies. The aim of the study was to evaluate the practical use of the drug based on release-active antibodies to interferone-y,CD4+receptor and histamine (Ergoferon) in ambulatory practice, including cases of late-start treatment and cases with allergic status of patients. Data of pediatric and adult patients who were ambulatory observed with influenza/ARVI diagnosis and used Ergoferon were included into the research. The physician set duration and scheme of the therapy. The received results were estimated retrospectively. The research was carried out with general practitioners from Azerbaijan, Armenia, Georgia, Kazakhstan, Kyrgyzstan, Mongolia, Tajikistan and Uzbekistan; period of observation - epidemiological season 2016-2017. 8411 patients (6005 infants, 2069 adults, 337 without specifications of the age) took part in the research. 706 patients had such allergy manifestations as allergic rhinitis/sinusitis, atopic dermatitis/eczema, bronchial asthma. The duration of the disease before the resolution of all the symptoms was on average 4.84±1.53 days; patients who started treatment from the first day of disease the duration was 4.79±1.44 days UNOVA, factor «the day of the start of therapy» χ2=31.15, df=3, p <0.001). Although the early-start treatment is important, the difference between the duration of all symptoms of the disease in both groups was only 0.39 day (9.4 hours). Therefore the conclusion has been made that Ergoferon has combined antiviral, anti-inflammatory and antihistamine effect only in case of prompt relief of ARVI and influenza symptoms in different terms of the beginning of the therapy independently of the age of patients, and including patients with an allergic status.